$761 Million is the total value of Broadfin Capital, LLC's 50 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 46.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZGNX | Sell | ZOGENIX INC | $19,542,000 | -40.1% | 535,998 | -18.5% | 2.57% | -46.5% |
| LJPC | Sell | LA JOLLA PHARMACEUTICAL CO | $18,365,000 | -55.6% | 1,947,541 | -5.2% | 2.42% | -60.3% |
| NSTG | Sell | NANOSTRING TECHNOLOGIES INC | $10,686,000 | -29.5% | 720,600 | -15.2% | 1.40% | -37.0% |
| ADMA | Sell | ADMA BIOLOGICS INC | $10,100,000 | -63.6% | 4,226,077 | -5.3% | 1.33% | -67.4% |
| ATRS | Sell | ANTARES PHARMA INC | $9,368,000 | -39.7% | 3,444,147 | -25.5% | 1.23% | -46.1% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $8,484,000 | -49.6% | 200,000 | -44.1% | 1.12% | -55.0% |
| SSKN | Sell | STRATA SKIN SCIENCES INC | $5,646,000 | -26.9% | 2,171,363 | -0.5% | 0.74% | -34.7% |
| TLGT | Sell | TELIGENT INC NEW | $3,868,000 | -67.9% | 2,823,383 | -7.5% | 0.51% | -71.3% |
| TNDM | Sell | TANDEM DIABETES CARE INC | $3,383,000 | -86.2% | 89,100 | -84.5% | 0.44% | -87.7% |
| HRTX | Sell | HERON THERAPEUTICS INC | $3,094,000 | -66.4% | 119,294 | -59.0% | 0.41% | -70.0% |
| KALV | Sell | KALVISTA PHARMACEUTICALS INC | $2,827,000 | -14.8% | 143,129 | -4.6% | 0.37% | -23.8% |
| KALA | Sell | KALA PHARMACEUTICALS INC | $1,658,000 | -51.5% | 339,119 | -2.0% | 0.22% | -56.7% |
| IDRA | Sell | IDERA PHARMACEUTICALS INC | $1,348,000 | -76.0% | 486,604 | -22.7% | 0.18% | -78.5% |
| NVLNF | Sell | NOVELION THERAPEUTICS INC | $1,033,000 | -82.1% | 1,229,301 | -36.9% | 0.14% | -84.0% |
| ATEC | Sell | ALPHATEC HOLDINGS INC | $1,030,000 | -54.4% | 449,585 | -32.9% | 0.14% | -59.3% |
| OMED | Exit | ONCOMED PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -0.06% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL COcall | $0 | – | -100,000 | -100.0% | -0.30% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -1,885,904 | -100.0% | -0.33% | – |
| HRTX | Exit | HERON THERAPEUTICS INCcall | $0 | – | -100,000 | -100.0% | -0.47% | – |
| Exit | PERNIX THERAPEUTICS HLDGS INdbcv 4.250% 4/0 | $0 | – | -15,000,000 | -100.0% | -0.50% | – | |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -62,200 | -100.0% | -0.80% | – |
| ANGO | Exit | ANGIODYNAMICS INC | $0 | – | -289,035 | -100.0% | -0.92% | – |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -410,532 | -100.0% | -1.18% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -895,553 | -100.0% | -1.74% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -2,493,021 | -100.0% | -1.98% | – |
| CORI | Exit | CORIUM INTL INC | $0 | – | -2,368,557 | -100.0% | -3.32% | – |
| AMRN | Exit | AMARIN CORP PLCcall | $0 | – | -1,455,000 | -100.0% | -3.48% | – |
| IWM | Exit | ISHARES TRput | $0 | – | -400,000 | -100.0% | -9.92% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.